Targeting of Notch, IL-1, and leptin has therapeutic potential in xenograft colorectal cancer


Creative Commons License

Ozyurt R., Erkasap N., Ozkurt M., Erkasap S. M., Dımas K., Çakır Gündoğdu A., ...Daha Fazla

Turkish Journal of Biology, cilt.47, sa.4, ss.290-300, 2023 (SCI-Expanded) identifier identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 47 Sayı: 4
  • Basım Tarihi: 2023
  • Doi Numarası: 10.55730/1300-0152.2663
  • Dergi Adı: Turkish Journal of Biology
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, BIOSIS, CAB Abstracts, Veterinary Science Database, TR DİZİN (ULAKBİM)
  • Sayfa Sayıları: ss.290-300
  • Eskişehir Osmangazi Üniversitesi Adresli: Evet

Özet

Background/aim: Colorectal cancer (CRC) is a fatal malignancy type and its occurence still needs to be explored mechanistically. Notch, IL-1, and leptin crosstalk is reported to play a role in the proliferation, migration, and expression of proangiogenic molecules. In this study, we aimed to investigate the effect of inhibition of Notch, IL-1, and leptin on CRC. Materials and methods: To generate colorectal cancer tumor xenografts, 1 × 10 7 cells from exponentially growing cultures of HCT- 15 cells were injected subcutaneously, at the axillary region of the left and right rear flanks of forty $NOD.CB17-Prkd^{cscid}/J (NOD/SCID)$ female mice. The mice were then monitored for the development of tumors and were randomly divided into five groups when tumor sizes reached a volume of approximately 150 mm3. Mice were used to determine the effectiveness of the gamma-secretase inhibitor (DAPT, Notch inhibitor), the interleukin-1 receptor antagonist (Anakinra) and the leptin receptor antagonist (Allo aca) against tumor growth. The mice were euthanized by $CO_2$ inhalation immediately after the treatments finished, and all efforts were made to minimize suffering. Tumors were excissed for RT-PCR and histological analysis. Results: There is an intact Notch, IL-1, and leptin signaling axis, and in vivo antagonism of Notch, IL-1, and leptin affects mRNA and protein expression of inflammatory and angiogenic molecules. Conclusion: Present data suggest that targeting Notch, IL-1, and leptin may be possesses therapeutic potential in CRC.